鄢龙家简介
鄢龙家，男，1984年10月，吉林大学博士学位，贵州大学副教授，硕士研究生导师，主要从事小分子酪氨酸激酶抑制剂类靶向抗肿瘤药物，阿尔茨海默病生物标志物的小分子诊断试剂，杂环化合物合成方法学研究，已发表论文二十余篇，中科院SCI分区二区及以上论文十余篇。在小分子抗肿瘤靶向药物和小分子荧光探针成像领域取得了大量的成果。
邮箱：ylj1089@163.com
2003年9月-2007年6月，吉林大学，化学学院，化学，学士
2007年9月-2012年12月，吉林大学，化学学院，有机化学，博士(导师：柏旭教授 裴亚中教授)
2013年1月-2017年6月，康龙化成新药技术有限公司，课题组长
2017年7月-2019年8月，广东工业大学，Meunier现代有机化学实验室，博士后 (导师：陈惠雄教授)
2019年10月至2023年12月，贵州大学，博鱼平台，校聘副教授
2024年1月至今，贵州大学，博鱼平台，副教授
【学术兼职及荣誉称号】
1.贵州大学2021年教师教学大赛理农组一等奖
2.贵州大学2023年教师教学创新大赛优秀奖;
3.贵州大学2023年青年教学能手
4.贵州省2023年“金课”药物化学课程负责人
5.贵州大学2023年教师教学大赛理农组二等奖
【主持项目】
1. 贵州大学人才引进项目：新型嘧啶类Src激酶抑制剂的合成和作用机制研究，2020.01-2022.12，项目经费：3.5万元 (已结题)
2. 贵州大学培育项目：新型嘧啶类靶向非小细胞肺癌的EGFR 和Src 双靶点抗肿瘤药物的合成与构效关系研究，2020.10-2023.10，项目经费：6万元 (已结题)
3. 省部共建药用植物功效与利用国家重点实验室开放课题项目：EGFR 和 Src 双靶点抑制剂的设计合成与抗肿瘤活性研究，2021.01-2022.12，项目经费：8万元 (已结题)
4. 贵州省科技计划项目：含噻吩片段的嘧啶类EGFR/Src双重抑制剂的设计合成与抗肿瘤活性研究，2022.04-2023.08，项目经费：10万元 (已结题)
5. 贵州省科技计划项目：基于前药策略的FAK/DNA双重抑制剂的分子构建与抗脑胶质瘤活性研究，2024.01-2027.12，项目经费：30万元(在研)
【近期发表论文】
1. Yongliang Li†, Jing Cai†, Longjia Yan†, Wanzheng Zhang, Li Li, Zhi-yun Du, Yanxiong Fang, Chang-zhi Dong, Bernard Meunier and Huixiong Chen*. Phenothiazine-based theranostic compounds for in vivo near-infared fluorescence imaging of β-amyloid plaques and inhibition of Aβ aggregation. Dyes and Pigments, 2019, 171, 107744.
2. Yongliang Li†, Longjia Yan†, Jing Cai†, Wanzheng Zhang, Li Li, Zhi-yun Du, Chang-zhi Dong, Bernard Meunierand Huixiong Chen*. Development of novel theranostic agents for in vivo amyloid imaging and protective effects on human neuroblastoma cells. European Journal of Medicinal Chemistry, 2019, 181, 111585.
3. Yi Le†, Yiyuan Gan†, Yihong Fu, Jiamin Liu, Wen Li, Xue Zou, Zhixu Zhou, Zhenchao Wang*, Guiping Ouyang* and Longjia Yan*. Design, synthesis and in vitro biological evaluation of quinazolinone derivatives as EGFR inhibitors for antitumor treatment. Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, 35, 555-564
4. Qing Wang, Dan Li, Nian Rao, Yan Zhang, Yi Le, Li Liu*, Lei Huang and Longjia Yan*. Development of indole-based fluorescent probe for detection of fluoride and cell imaging of HepG2. Dyes and Pigments, 2021, 188, 109166.
5. Yan Zhang, Qin Wang, Luolan Li, Yi Le*, Li Liu, Jing Yang, Yongliang Li*, Guochen Bao and Longjia Yan*. Synthesis and preliminary structure-activity relationship study of 3-methylquinazolinone derivatives as EGFR inhibitors with enhanced antiproliferative activities against tumor cells. Journal of Enzyme Inhibition and Medicinal Chemistry, 2021, 36, 1205-1216.
6. Longjia Yan, Dan Li, Yi Le, Ping Dong and Li Liu*. Phenothiazine-based fluorescent probe for fluoride ions and its applications in rapid detection of endemic disease. Dyes and Pigments, 2022, 201, 110200.
7. Longjia Yan, Qin Wang, Li Liu andYi Le*. Design, synthesis and biological evaluation of a series of dianilinopyrimidines as EGFR inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2022, 37, 832-843.
8. Yaqing Zuo, Rongrong Li, Yan Zhang, Guochen Bao, Yi Le, and Longjia Yan*. Design, synthesis and antitumor activity of 5-trifluoromethylpyrimidine derivatives as EGFR inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2022, 37, 2742-2754.
9. Yan Zhang, Zhiwu Long, Nian Rao, Yi Le, Li Liu, and Longjia Yan*. New phenylisoxazole derivatives: Synthesis, Spectroscopic, X-ray, IR, DFT calculation and biological activity studies. Journal of Molecular Structure, 2023, 1285, 135557.
10. Zhiwu Long, Yaqing Zuo, Rongrong Li, Yi Le, Yawen Dong, Longjia Yan*. Design, synthesis and biological evaluation of 4-arylamino-pyrimidine derivatives as focal adhesion kinase inhibitors. Bioorganic Chemistry, 2023, 140, 106792.
11. Yongliang Li†, Longjia Yan†, Huixiong Chen*, Bankang Ruan, Pascal Dao, Du, Zhiyun Du*, Changzhi Dong, Bernard Meunier. Design, synthesis and evaluation of novel pyrimidinylaminothiophene derivatives as FGFR1 inhibitors against human glioblastoma multiforme. European Journal of Medicinal Chemistry, 2023, 260, 115764.
12. Yaqing Zuo, Zhiwu Long, Rongrong Li Yi Le, Silong Zhang, Huan He, Longjia Yan*. Design, synthesis and antitumor activity of 4-arylamine substituted pyrimidine derivatives as noncovalent EGFR inhibitors overcoming C797S mutation. European Journal of Medicinal Chemistry, 2024, 265, 116106.
